Accelerating Clinical Development with ctDNA Clearance & Multi-Omic Profiling

• Using ctDNA clearance timepoints to optimize dose selection and accelerate internal go or no-go decisions across modalities under Project Optimus
• Expanding beyond mutation profiling through multi-omic approaches to better track resistance, cell surface targets, and combination strategy rationale
• Advancing standardization and regulatory alignment for complex assays throughcollaborative initiatives such as BLOODPAC

Speakers:

Rebecca Leary

Lab Head & Director, Next-Generation Diagnostics

Novartis